Enzalutamide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Enzalutamide

Examples of brand names: Xtandi [EU/DE]

ATC code: L02BB04

Main use (for orientation): Prostate cancer

Documented research summary

Preclinical combination signals from 2026, but the abstract does not distinguish additive/synergistic effects for each pair. No clinical CBD–enzalutamide drug–drug interaction established.

Uncertainties and limitations

Human oral XTANDI, capsules/tablets in the label.

Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0192

Type of result: Preclinical evidence

Observation: Combination with hormonal/targeted therapies showed additive or synergistic cellular effects; exact classification for enzalutamide not separated in the abstract.

Mechanism: Epigenome/cell cycle

Study type: Cell / animal experiment, abstract read

Context studied: Prostate cancer cell lines; no specific effect size available for the pair.

Clinical interpretation: Not clinically validated

Limitations and uncertainties: Hypothesis-generating; full text needed for an unambiguous enzalutamide combination effect.

Original sources for this finding: Cannabidiol alters the epigenome of hormone-dependent prostate cancer cells. [BMED42691574]

References and access status

[V2_LABEL_D0400] XTANDI (ENZALUTAMIDE) CAPSULE XTANDI (ENZALUTAMIDE) TABLET [ASTELLAS PHARMA US, INC.]

Original source / bibliographic reference

Authors: Astellas Pharma US, Inc.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED42691574] Cannabidiol alters the epigenome of hormone-dependent prostate cancer cells.

Original source / bibliographic reference

Authors: Cosgrave J, Magee R, O'reilly E, Hughes C, Jordan A, Silva R, Mccabe A, Dean K, Prencipe M, Gallagher WM, Perry AS.

Year: 2026

Source type: Publication; title and abstract reviewed

DOI: 10.1016/j.biopha.2026.119891

PMID: 42691574

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility